fenoterol

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

About Ask DrugCentral

Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.

General architecture

Ask a questionThe browser sends your question to the same-origin Django chat API.
Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.

Using the assistant

Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.

Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.

Dose	Unit	Route
0.60	mg	Inhal.aerosol
0.60	mg	Inhal.powder
4	mg	Inhal.solution
10	mg	O
10	mg	R

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.08 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Hosey CM, Chan R, Benet LZ
BA (Bioavailability)	2 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.20 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	29 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.53 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.87 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	0.16 mg/mL	Bocci G, Oprea TI, Benet LZ

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	0.238		High	1
caco2-efflux	Caco-2 efflux ratio (BA/AB)	1.633		High	1
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	0.341	10^-6 cm/s	High	1
dh-clint	Dog hepatocyte intrinsic clearance	3.981	uL/min/10^6 cells	High	1
dppb	Dog plasma protein binding (% unbound)	55.390	%	High	1
fcs-ppb	Fetal calf serum protein binding (% unbound)	49.540	%	High	1
herg	hERG pIC50	4.176	pIC50	High	1
hh-clint	Human hepatocyte intrinsic clearance	2.317	uL/min/10^6 cells	High	1
hlm-clint	Human liver microsomal intrinsic clearance	4.150	uL/min/mg protein	High	1
hppb	Human plasma protein binding (% unbound)	60.990	%	High	1
kinase-safety-class	ACVR2A,ACVR2B,AKT2,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK2,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,ITK,JAK1,JAK2,JAK3,KIT,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MTOR,NTRK2,PDK1,PDK2,PDPK1,PIK3CB,PIM2,PLK1,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70	53
kinase-selectivity-class	ACVR2B,AXL,GRK2,MAP2K6,TEK	5
mdck-mdr1-bcrp-efflux	MDCK-MDR1-BCRP efflux ratio	0.577		High	1
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	0.570		High	1
mh-clint	Mouse hepatocyte intrinsic clearance	76.384		High	1
mppb	Mouse plasma protein binding (% unbound)	54.140		High	1
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	0.813		High	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pld-class	Phospholipidosis risk class (1 = positive, 0 = negative)	0		High	1
pppb	Pig plasma protein binding (% unbound)	56.190	%	High	1
rat-kpuu-brain	Rat brain Kpuu	0.009	%	High	1
rh-clint	Rat hepatocyte intrinsic clearance	15.453	uL/min/10^6 cells	High	1
rh-fuinc	Rat hepatocyte fraction unbound in incubation	79.210	%	High	1
rppb	Rat plasma protein binding (% unbound)	40.500	%	High	1
solubility-dd	Solubility at pH 7.4 in DMSO	860.994	uM	High	1

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Congenital coronary artery malformation	70.48	34.00	10	1818	149	90626470
Polyneuropathy	51.45	34.00	18	1810	19323	90607296
Acute respiratory failure	50.17	34.00	22	1806	42896	90583723
Sinus arrhythmia	48.41	34.00	10	1818	1439	90625180
Polyhydramnios	48.29	34.00	11	1817	2497	90624122
Arterial thrombosis	47.42	34.00	10	1818	1590	90625029
Pancreatic steatosis	47.16	34.00	10	1818	1632	90624987
Cervical incompetence	43.37	34.00	8	1820	640	90625979
Erysipelas	38.45	34.00	12	1816	9040	90617579

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Appendicolith	163.15	34.67	63	5635	13393	42602244
Myasthenia gravis	162.29	34.67	66	5632	16071	42599566
Blood phosphorus increased	156.71	34.67	60	5638	12465	42603172
Hyperphosphataemia	143.94	34.67	57	5641	12947	42602690
Appendicitis	140.38	34.67	64	5634	20549	42595088
Blood uric acid increased	124.21	34.67	54	5644	15493	42600144
Bacterial infection	116.34	34.67	62	5636	27817	42587820
Ventricular fibrillation	114.59	34.67	63	5635	30060	42585577
Chronic obstructive pulmonary disease	113.39	34.67	82	5616	63032	42552605
Hypophosphataemia	111.81	34.67	55	5643	20890	42594747
Neuralgia	109.73	34.67	58	5640	25589	42590048
Iron deficiency	106.93	34.67	44	5654	11017	42604620
Cardiogenic shock	104.72	34.67	63	5635	35577	42580060
Stress	99.48	34.67	66	5632	44146	42571491
Dry mouth	98.21	34.67	63	5635	39816	42575821
Blood cholesterol increased	96.41	34.67	54	5644	26687	42588950
Incorrect route of product administration	92.87	34.67	51	5647	24254	42591383
Sleep disorder therapy	89.69	34.67	34	5664	6860	42608777
Analgesic therapy	87.86	34.67	33	5665	6491	42609146
Drug therapy	84.93	34.67	32	5666	6348	42609289
Abdominal distension	83.08	34.67	72	5626	71663	42543974
Ascites	80.42	34.67	64	5634	56614	42559023
Thrombosis	77.79	34.67	68	5630	68443	42547194
Diabetes mellitus	75.05	34.67	63	5635	60024	42555613
Swelling	73.66	34.67	60	5638	54825	42560812
Intentional product misuse	69.37	34.67	61	5637	61839	42553798
Sleep disorder	67.54	34.67	54	5644	48041	42567596
General physical health deterioration	65.03	34.67	90	5608	151156	42464481
Hyponatraemia	55.45	34.67	68	5630	101394	42514243
Multiple organ dysfunction syndrome	54.59	34.67	66	5632	96969	42518668
Pulmonary embolism	54.12	34.67	73	5625	119539	42496098
Drug intolerance	49.02	34.67	57	5641	80367	42535270
Somnolence	47.66	34.67	75	5623	141030	42474607
Drug hypersensitivity	39.46	34.67	57	5641	99332	42516305
Activated partial thromboplastin time prolonged	38.79	34.67	25	5673	15878	42599759
Constipation	37.50	34.67	73	5625	162218	42453419
Congenital cystic lung	36.49	34.67	8	5690	223	42615414

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

fenoterol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Appendicolith	208.07	28.45	64	7145	14191	110567899
Myasthenia gravis	193.77	28.45	67	7142	21444	110560646
Blood phosphorus increased	187.23	28.45	61	7148	16279	110565811
Hyperphosphataemia	171.00	28.45	57	7152	16324	110565766
Appendicitis	168.29	28.45	65	7144	28399	110553691
Chronic obstructive pulmonary disease	156.26	28.45	94	7115	109064	110473026
Ventricular fibrillation	144.90	28.45	65	7144	41248	110540842
Blood uric acid increased	144.70	28.45	54	7155	21475	110560615
Hypophosphataemia	125.33	28.45	55	7154	33127	110548963
Cardiogenic shock	121.78	28.45	64	7145	57274	110524816
Bacterial infection	119.96	28.45	59	7150	45977	110536113
Neuralgia	117.07	28.45	59	7150	48419	110533671
Iron deficiency	115.65	28.45	44	7165	18432	110563658
Sleep disorder therapy	115.19	28.45	35	7174	7436	110574654
Analgesic therapy	111.77	28.45	34	7175	7250	110574840
Drug therapy	107.48	28.45	33	7176	7258	110574832
Ascites	102.84	28.45	68	7141	92740	110489350
Stress	92.74	28.45	67	7142	105281	110476809
Diabetes mellitus	91.60	28.45	65	7144	99316	110482774
Thrombosis	84.18	28.45	64	7145	108598	110473492
Incorrect route of product administration	83.47	28.45	52	7157	64009	110518081
Abdominal distension	81.70	28.45	77	7132	175026	110407064
General physical health deterioration	75.43	28.45	114	7095	425181	110156909
Hyponatraemia	74.61	28.45	81	7128	217572	110364518
Multiple organ dysfunction syndrome	73.23	28.45	68	7141	151642	110430448
Intentional product misuse	68.88	28.45	62	7147	132842	110449248
Pulmonary embolism	68.63	28.45	77	7132	214397	110367693
Somnolence	64.83	28.45	88	7121	297361	110284729
Congenital coronary artery malformation	60.98	28.45	10	7199	117	110581973
Dry mouth	52.67	28.45	65	7144	199883	110382207
Anaemia	47.70	28.45	108	7101	546978	110035112
Benign prostatic hyperplasia	46.36	28.45	23	7186	18211	110563879
Sepsis	45.98	28.45	79	7130	327267	110254823
Constipation	45.93	28.45	83	7126	357703	110224387
Activated partial thromboplastin time prolonged	44.72	28.45	24	7185	22344	110559746
Congenital hiatus hernia	43.13	28.45	16	7193	6243	110575847
Blood cholesterol increased	42.23	28.45	56	7153	184729	110397361
Acute respiratory failure	36.79	28.45	34	7175	75226	110506864
Sleep disorder	36.18	28.45	54	7155	198590	110383500
Abdominal pain	35.81	28.45	93	7116	512896	110069194
Cardiac failure	35.60	28.45	52	7157	187574	110394516
Bronchopulmonary aspergillosis allergic	35.17	28.45	15	7194	8411	110573679
End stage renal disease	34.61	28.45	20	7189	21453	110560637
Pancreatic steatosis	34.46	28.45	10	7199	1812	110580278
Anticoagulant therapy	34.37	28.45	13	7196	5348	110576742
Antacid therapy	34.09	28.45	13	7196	5471	110576619
Presyncope	33.92	28.45	27	7182	48860	110533230
Polyhydramnios	33.87	28.45	10	7199	1923	110580167
Sinus arrhythmia	32.73	28.45	10	7199	2160	110579930
Xanthelasma	31.81	28.45	6	7203	163	110581927
Atrioventricular block	30.66	28.45	17	7192	16860	110565230
Condition aggravated	30.46	28.45	111	7098	734725	109847365
Cervical incompetence	30.00	28.45	7	7202	540	110581550
Bacteroides infection	29.82	28.45	10	7199	2909	110579181
Gout	29.30	28.45	22	7187	36544	110545546
Arterial thrombosis	29.17	28.45	10	7199	3109	110578981
Rash	28.61	28.45	9	7200	820955	109761135

Source	Code	Description
ATC	G02CA03	GENITO URINARY SYSTEM AND SEX HORMONES OTHER GYNECOLOGICALS OTHER GYNECOLOGICALS Sympathomimetics, labour repressants
ATC	R03AC04	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Selective beta-2-adrenoreceptor agonists
ATC	R03AL01	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
ATC	R03CC04	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS FOR SYSTEMIC USE Selective beta-2-adrenoreceptor agonists
MeSH PA	D000318	Adrenergic beta-Agonists
MeSH PA	D001993	Bronchodilator Agents
MeSH PA	D012102	Reproductive Control Agents
MeSH PA	D013566	Sympathomimetics
MeSH PA	D015149	Tocolytic Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D018927	Anti-Asthmatic Agents
MeSH PA	D019141	Respiratory System Agents
MeSH PA	D058666	Adrenergic beta-2 Receptor Agonists
CHEBI has role	CHEBI:35522	β-adrenergic agonist
CHEBI has role	CHEBI:35523	bronchodilator agent
CHEBI has role	CHEBI:35524	sympathomimetic agent
CHEBI has role	CHEBI:35554	cardiovascular drug
CHEBI has role	CHEBI:65023	anti-asthmatic agent
CHEBI has role	CHEBI:66993	tocolytic agent

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.48	acidic
pKa2	11.02	acidic
pKa3	11.67	acidic
pKa4	12.2	acidic
pKa5	8.03	Basic

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN	AGONIST	EC50	6.90	WOMBAT-PK	IUPHAR
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN	AGONIST	EC50	7.50	IUPHAR
Beta-3 adrenergic receptor	GPCR	P13945	ADRB3_HUMAN	AGONIST	EC50	7.60	IUPHAR
Beta-3 adrenergic receptor	GPCR	P13945	ADRB3_HUMAN	AGONIST	EC50	7.60	IUPHAR
Beta-2 adrenergic receptor	GPCR		ADRB2_CAVPO		IC50	7.22	CHEMBL

ID	Source
4025246	VUID
N0000171778	NUI
D01428	KEGG_DRUG
4025246	VANDF
C0015840	UMLSCUI
CHEBI:149226	CHEBI
ZVJ	PDB_CHEM_ID
CHEMBL32800	ChEMBL_ID
DB01288	DRUGBANK_ID
D005280	MESH_DESCRIPTOR_UI
3343	PUBCHEM_CID
557	IUPHAR_LIGAND_ID
3073	INN_ID
36369-23-0	SECONDARY_CAS_RN
22M9P70OQ9	UNII
203124	RXNORM
003460	NDDF
003461	NDDF
349924004	SNOMEDCT_US
395976006	SNOMEDCT_US
396053003	SNOMEDCT_US
1944-10-1	SECONDARY_CAS_RN
130156-24-0	SECONDARY_CAS_RN
22M9P70OQ9	INXIGHT DRUGS